Does the Risk of Embryo Abnormality Increase in Polycystic Ovary Syndrome (PCOS) Women? A Secondary Analysis of a Multicenter, Randomized Controlled Trial
Primary result · Embryonic aneuploid rateResult — go to the resultAdjusted odds ratio 0.78 95% CI 0.54–1.12Authors' conclusion
The risk of aneuploid and mosaic embryos did not increase in PCOS women. Thus, we suggest that the miscarriage rate arising from abnormal embryonic chromosomes could be similar between PCOS and non-PCOS women.
Study context
- Population
- Patients from the preimplantation genetic test for aneuploidy (PGT-A) group of an RCT of PGT-A vs in vitro fertilization (IVF), 14 reproductive centers, July 2017 to June 20181,118 embryos
- Participants
- 380 patients
- Comparison
- PCOS vs age-matched non-PCOS women undergoing PGT-A
- PCOSn = 190
- Primary endpoint
- Embryonic aneuploidy and embryonic mosaic
Methodological details1:1 age-matched
- 1:1 age-matched
Primary result
Embryonic aneuploid rate
Adjusted odds ratio
0.78
95% CI 0.54–1.12
P = 0.19
By group
PCOSvs Control
aOR 0.78 (95% CI 0.54–1.12); P = 0.19
As reported in the abstract
Further findings
| Outcome | PCOS | Control | aOR (95% CI) | P value | |
|---|---|---|---|---|---|
| Embryonic mosaic rateCo-primary main outcome measure | 10.9% | 10.1% | 0.91 (0.59–1.40) | P = 0.66 | |
| 0.512Adjusted odds ratio (log scale) |
Aneuploid and mosaic embryos by PCOS phenotype (4 groups)
- Rates comparable between each PCOS phenotype and control group
- No significant difference among the 4 phenotypes
Original publication
Does the Risk of Embryo Abnormality Increase in PCOS Women? A Secondary Analysis of a Multicenter, Randomized Controlled Trial. J Clin Endocrinol Metab. Published 21 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →